Effects of dexmedetomidine on immune and analgesic in perioperative patients undergoing neurosurgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IIR-17011924

Enrollment

Unknown

Registered

2017-07-10

Start date

2017-07-01

Completion date

Unknown

Last updated

2020-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracranial tumor

Interventions

Dexmedetomidine :Dexmedetomidine

control:saline

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 60 patients under general anesthesia for neurosurgery surgery, ASA I or II, without preoperative infection, immune and endocrine system disease, radiotherapy and chemotherapy and blood transfusion treatment, did not receive any drug (including immunomodulator treatment)

Exclusion criteria

Exclusion criteria: patients without preoperative infection, immune and endocrine system disease, radiotherapy and chemotherapy and blood transfusion treatment, did not receive any drug (including immunomodulator treatment)

Design outcomes

Primary

Measure	Time frame
endothelin;NK cell;TNF-a mRNA;	—

Countries

China

Contacts

Public ContactChen Hong

Harbin Medical University Cancer Hospital

517891483@qq.com+86 13945666776

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026